CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0030731: CarcinomaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (17)


Name (Synonyms) Correlation
drug614 Carboplatin Wiki 0.63
drug753 Convalescent Plasma (CP) Wiki 0.63
drug931 Drugs and supportive care Wiki 0.45
drug2363 Radspherin Wiki 0.45
drug392 Berzosertib Wiki 0.45
drug36 30 Gy over 3 weeks Wiki 0.45
drug1065 F-FMISO PET/CT Scan Wiki 0.45
drug2676 Standard COVID-19 therapies Wiki 0.45
drug909 Docetaxel Wiki 0.45
drug3362 nasopharyngeal Covid 19 RT-PCR Wiki 0.45
drug51 5Fluorouracil Wiki 0.45
drug673 Cisplatin Wiki 0.45
drug1546 Laboratory Biomarker Analysis Wiki 0.45
drug2262 Proton Therapy Wiki 0.45
drug752 Convalescent Plasma Wiki 0.27
drug344 BI 894999 Wiki 0.26
drug2122 Placebo Wiki 0.02

Correlated MeSH Terms (7)


Name (Synonyms) Correlation
D002277 Carcinoma NIH 1.00
D002294 Carcinoma, Squamous Cell NIH 0.45
D000077216 Carcinoma, Ovarian Epithelial NIH 0.45
D010534 Peritoneal Neoplasms NIH 0.45
D006528 Carcinoma, Hepatocellular NIH 0.45
D010051 Ovarian Neoplasms NIH 0.32
D011471 Prostatic Neoplasms NIH 0.22

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0002860 Squamous cell carcinoma HPO 0.45
HP:0001402 Hepatocellular carcinoma HPO 0.45
HP:0100615 Ovarian neoplasm HPO 0.32
HP:0012125 Prostate cancer HPO 0.22

There are 5 clinical trials

Clinical Trials


1 An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit

The aim of the phase Ia (dose escalation) part of this trial is to assess-> determine the Maximum Tolerated Dose (MTD) using a continuous dosing schedule A, using an intermittent Schedule B (2 weeks on, one week off in 3-week cycles) and the MTD using an intermittent Schedule C (one week on followed by one week off treatment, repeated every two weeks in 4-week cycles) in patients with solid tumours. In the phase Ib expansion part, the aim is to further evaluate the safety profile of BI 894999 at the dose recommended by the data monitoring committee (DMC). Once the MTD has been determined for both schedules A and B in patients with solid tumours, the MTD will be determined as well in patients with diffuse large B-cell lymphoma (DLBCL), using the DMC recommended schedule for solid tumours

NCT02516553 Neoplasms NUT Carcinoma Drug: BI 894999 Drug: BI 894999 Drug: BI 894999
MeSH:Carcinoma
HPO:Carcinoma

Primary Outcomes

Measure: In phase Ib: Number of patients experiencing DLTs from start of treatment until end of treatment (in all cycles) as assessed approximately every 3 weeks after Cycle 2 (at the end of each new cycle) in order to determine the recommended phase II dose

Time: average of 12 months

Measure: In phase Ia: Number of patients with DLT observed in the first cycle (first 21 days) for Schedules A and B, first 28 days for Schedule C), to meet objective of assessing MTD for each schedule in solid tumour patients & in schedule B in the DLBCL cohort

Time: Up to 4 weeks

Secondary Outcomes

Measure: efficacy endpoint in phases Ia and Ib: Objective response (OR), defined as CR or PR with tumour assessment during treatment period for each schedule

Time: every 6 weeks, average of 4 months

Measure: efficacy endpoint in phase Ib: Progression-free Survival (PFS) or radiological PFS

Time: average of 5 months

Measure: efficacy endpoint in phase Ib: Best overall response with an evaluation of approximately every 2 cycles (6 weeks if no delays) during the entire treatment period

Time: every 6 weeks, average of 4 months

Measure: In both phases: Cmax,ss after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C)

Time: up to 4 weeks

Measure: In both phases: AUC0-24 after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C)

Time: up to 4 weeks

Measure: In both phases: AUC tau, ss after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C)

Time: up to 4 weeks

Measure: Phase Ia: Number of patients experiencing DLTs from start of treatment until end of treatment (in all cycles) for each of the schedules (A, B and C) in patients with solid tumours and in schedule B in the DLBCL cohort

Time: average of 12 months

Measure: In both phases: Cmax after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C)

Time: up to 4 weeks

Measure: efficacy endpoint in phase Ib: Prostate Specific Antigen (PSA) response (decline in PSA value ≥50% from baseline) in patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Time: average of 12 months

Measure: Overall survival in patients with NUT Carcinoma (NC)

Time: Up to 29 months

2 A Prospective Single Arm Non-inferiority Trial of Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma (Major De-escalation to 30Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma)

The purpose of this study is to demonstrate that participants with HPV positive and hypoxia negative T1-2, N1-2c (AJCC, 7th ed.) oropharyngeal squamous cell carcinoma receiving a major de-escalated radiation therapy with 2 cycles of standard chemotherapy is not inferior to comparable subjects treated with the current standard chemoradiation. Given the restrictions of surgery during the COVID19 pandemic, we will start enrolling patients on Cohort B where surgery is not required. Once the COVI19 pandemic is over, we will resume and complete enrollment on Cohort A where surgery is required, prior to continuing enrolling patients on Cohort B. During the COVID-19 pandemic, the research MRIs are optional.

NCT03323463 HPV-Associated Oropharyngeal Squamous Cell Carcinoma Squamous Cell Carcinoma of the Neck Diagnostic Test: F-FMISO PET/CT Scan Radiation: 30 Gy over 3 weeks Drug: Cisplatin Drug: Carboplatin Drug: 5Fluorouracil Radiation: Proton Therapy
MeSH:Carcinoma Carcinoma, Squamous Cell
HPO:Carcinoma Squamous cell carcinoma

Primary Outcomes

Measure: Effectiveness of study treatment for participants receiving de-escalated radiation therapy radiation therapy, comparable to participants treated with the current standard of care chemoradiation by standard CT (or MRI) or tumor site and PET scan

Time: 2 years (+/- 3 months)

3 A Phase 2 Study of M6620 in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer

This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

NCT03517969 Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IV Prostate Cancer AJCC v8 Drug: Berzosertib Drug: Carboplatin Drug: Docetaxel Other: Laboratory Biomarker Analysis
MeSH:Carcinoma Prostatic Neoplasms
HPO:Carcinoma Prostate cancer Prostate neoplasm

Primary Outcomes

Description: Defined by radiographic response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or prostate specific antigen [PSA] response of > 50%). Will be conducted using the Cochran-Mantel-Haenszel test, with one-sided p-value of =< 0.05 considered significant.

Measure: Response rate (complete response + partial response)

Time: Up to 2 years

Secondary Outcomes

Description: Assessed by Prostate Cancer Working Group (PCWG)3. PFS to be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval.

Measure: Progression-free survival (PFS)

Time: From the time of randomization up to 2 years

Description: Assessed by PCWG2. PSA progression will be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval. Comparison of time to PSA progression between arms will be conducted using the log-rank test.

Measure: Time to PSA progression

Time: From the time of randomization up to 2 years

Description: Assessed by RECIST 1.1. rPFS will be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval.

Measure: Radiographic progression-free survival (rPFS)

Time: From the time of randomization up to 2 years

Description: Will be summarized according to treatment arm. For toxicity reporting, all adverse events will be graded and analyzed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Type of adverse events, intensity (grading), and attribution will be provided in a listing. All adverse events resulting in discontinuation, dose modification, and/or dosing interruption, and/or treatment delay of drug will also be summarized. Laboratory test results will be classified according to the CTCAE version 5.0.

Measure: Incidence of adverse events

Time: Up to 2 years

Other Outcomes

Description: OS will be estimated with the Kaplan Meier methodology. Comparison of OS between arms will be conducted using the log-rank test base on the intention-to-treat approach, where two treatment arms will be compared regardless of cross-over or any subsequent therapy.

Measure: Overall survival (OS)

Time: From the time of randomization up to 2 years

Description: Gene mutation frequencies and mean +/- standard deviation of quantitative biomarkers will be summarized by arm and in overall population at baseline and/or at end of study.

Measure: Gene mutation frequencies

Time: Baseline up to 2 years

4 A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following CRS

RAD-18-001 is a First-In-Man, Dose Escaltion study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose Limiting Toxicicities (which will stop the dose escalation), this will be the recommended dose for further exploration. Acceptability of up to 7 MBq gives the opportunity to explore the doses of the dose escalation split into two administrations, and given as two separate injections 1 week apart. Split doses of 1, 2 and 3.5 MBq will be administered as two injections. Each subject will be followed until disease progression (in the abdominal cavity), or for 12 months after the administration of Radspherin® (whichever comes first).

NCT03732768 Peritoneal Carcinomatosis Ovarian Cancer Drug: Radspherin
MeSH:Ovarian Neoplasms Carcinoma, Ovarian Epithelial Carcinoma Peritoneal Neoplasms
HPO:Carcinoma Ovarian neoplasm

Primary Outcomes

Description: To investigate safety and toxicity of Radspherin®

Measure: Number of participants with Dose Limiting Toxicities as assessed by CTCAE v5.0.

Time: 12 months

Description: To determine the MTD of Radspherin®, among the four suggested doses 1, 2, 4 and 7 MBq, as a single intraperitoneal (IP) injection and two repeated IP injections following cytoreductive surgery (CRS)

Measure: Maximum Tolerated Dose (MTD)

Time: 21 days

5 Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort

Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic

NCT04367805 Hepatocellular Carcinoma COVID-19 Diagnostic Test: nasopharyngeal Covid 19 RT-PCR
MeSH:Carcinoma Carcinoma, Hepatocellular
HPO:Carcinoma Hepatocellular carcinoma

Primary Outcomes

Description: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Measure: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Time: 6 months


HPO Nodes